Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$665K Buy
23,682
+545
+2% +$14.5K 0.08% 83
2025
Q4
$576K Sell
23,137
-467
-2% -$11.8K 0.07% 116
2025
Q3
$601K Buy
23,604
+3,730
+19% +$92.1K 0.08% 106
2025
Q2
$482K Buy
19,874
+2,897
+17% +$67.6K 0.07% 127
2025
Q1
$430K Buy
16,977
+2,153
+15% +$56.3K 0.08% 129
2024
Q4
$393K Sell
14,824
-118
-0.8% -$3.2K 0.07% 136
2024
Q3
$432K Sell
14,942
-564
-4% -$16.5K 0.08% 127
2024
Q2
$434K Sell
15,506
-636
-4% -$17.5K 0.09% 127
2024
Q1
$448K Buy
16,142
+2,285
+16% +$63.4K 0.1% 118
2023
Q4
$399K Buy
13,857
+4,749
+52% +$144K 0.11% 94
2023
Q3
$302K Sell
9,108
-10,778
-54% -$381K 0.09% 100
2023
Q2
$729K Sell
19,886
-1,810
-8% -$70.5K 0.24% 48
2023
Q1
$885K Sell
21,696
-512
-2% -$22.1K 0.27% 36
2022
Q4
$1.14M Buy
22,208
+1,075
+5% +$51.5K 0.33% 40
2022
Q3
$925K Sell
21,133
-1,133
-5% -$55.1K 0.28% 38
2022
Q2
$1.17M Buy
22,266
+2,406
+12% +$123K 0.33% 33
2022
Q1
$1.03M Buy
19,860
+402
+2% +$20.9K 0.26% 47
2021
Q4
$1.1M Buy
19,458
+3,096
+19% +$153K 0.33% 44
2021
Q3
$704K Buy
16,362
+309
+2% +$13.7K 0.24% 56
2021
Q2
$629K Buy
16,053
+1,677
+12% +$65.2K 0.21% 57
2021
Q1
$521K Buy
14,376
+1,401
+11% +$49.7K 0.21% 61
2020
Q4
$478K Buy
+12,975
New +$476K 0.2% 63

Other funds holding PFE

MJP Associates's PFE Position: Q1 2026 in Review

MJP Associates increased its Pfizer (PFE) stake by 2.4% in Q1 2026, buying an estimated $14.5K and bringing the position to 23,682 shares worth $665K. The position accounts for 0.08% of the portfolio, ranked #83.

MJP Associates first reported a position in PFE in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.17M in Q2 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • MJP Associates held 23,682 shares of Pfizer worth $665K as of Q1 2026.
  • MJP Associates bought 545 Pfizer shares in Q1 2026, an estimated $14.5K.
  • Pfizer made up 0.08% of MJP Associates's portfolio in Q1 2026, its #83 holding.
  • MJP Associates first reported a position in Pfizer in Q4 2020 and has held it in 22 quarters since.
  • MJP Associates's Pfizer position peaked at $1.17M in Q2 2022.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.